Answers are grounded in this paper and cite their sources.
BACKGROUND: Women with ER-positive breast cancer may recur as late as 20 years post-diagnosis. The reason for this delayed recurrence is unknown. We studied survival patterns, including time-to-death in 123,705 women with stage I to III invasive breast cancer, enrolled in the SEER database. Among these 76.8% were ER-positive and 23.2% were ER-negative. METHODS: We divided the cohort into ten classes with varying risks of death from breast cancer. The 20-year mortality for women in the highest risk decile 10 was 69% versus 5% for women in the lowest decile 1. The difference in the time-to-death by decile could be explained by a variable α which represents the annual rate of reactivation from tumour dormancy. RESULTS: The duration of tumour dormancy was much longer, on average, for ER-positive breast cancers than for ER-negative breast cancers. Reactivation from tumour dormancy appears to occur at random and may explain the very long time to cancer recurrence in women with small node-negative ER-positive breast cancers. CONCLUSION: The clinical course of women with low-risk ER-positive breast cancer is inherently unpredictable and consequently death is equally as likely to occur at year 3 than at year 20.
No takes yet. Share an insight, caveat, or question.
Giannakeas et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: